Known targets — ChEMBL curated mechanism
ADRM1PSMA1PSMA2PSMA3PSMA4PSMA5PSMA6PSMA7PSMA8PSMB1PSMB10PSMB11PSMB2PSMB3PSMB4PSMB5PSMB6PSMB7PSMB8PSMB9PSMC1PSMC2PSMC3PSMC4PSMC5PSMC6PSMD1PSMD11PSMD12PSMD13PSMD14PSMD2PSMD3PSMD4PSMD6PSMD7PSMD8SEM1
The experimentally established mechanism targets of Ixazomib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 known ✓ | P28074 | 19/20 | 1.00 |
| ▸ | PSMB8 known ✓ | P28062 | 7/20 | 1.00 |
| ▸ | PSMB9 known ✓ | P28065 | 7/20 | 1.00 |
| ▸ | PSMB6 known ✓ | P28072 | 7/20 | 1.00 |
| ▸ | PSMB10 known ✓ | P40306 | 7/20 | 1.00 |
| ▸ | PSMB11 known ✓ | A5LHX3 | 6/20 | 1.00 |
| ▸ | PSMA7 known ✓ | O14818 | 6/20 | 1.00 |
| ▸ | PSMB1 known ✓ | P20618 | 6/20 | 1.00 |
| ▸ | PSMA1 known ✓ | P25786 | 6/20 | 1.00 |
| ▸ | PSMA2 known ✓ | P25787 | 6/20 | 1.00 |
| ▸ | PSMA3 known ✓ | P25788 | 6/20 | 1.00 |
| ▸ | PSMA4 known ✓ | P25789 | 6/20 | 1.00 |
| ▸ | PSMA5 known ✓ | P28066 | 6/20 | 1.00 |
| ▸ | PSMB4 known ✓ | P28070 | 6/20 | 1.00 |
| ▸ | PSMB3 known ✓ | P49720 | 6/20 | 1.00 |
| ▸ | PSMB2 known ✓ | P49721 | 6/20 | 1.00 |
| ▸ | PSMA6 known ✓ | P60900 | 6/20 | 1.00 |
| ▸ | PSMA8 known ✓ | Q8TAA3 | 6/20 | 1.00 |
| ▸ | PSMB7 known ✓ | Q99436 | 6/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ixazomib SCHEMBL18088836 | 1.00 | PSMB5 (1.00) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| Ixazomib SCHEMBL29353014 | 1.00 | PSMB5 (1.00) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL3753435 | 0.92 | PSMB5 (0.85) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL12391076 | 0.92 | PSMB5 (0.84) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL22604863 | 0.91 | PSMB5 (0.83) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL253622 | 0.91 | PSMB5 (0.83) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| Ixazomib SCHEMBL29454797 | 0.90 | PSMB5 (0.81) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL20694721 | 0.90 | PSMB5 (0.81) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL28826825 | 0.89 | PSMB5 (0.82) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL28826826 | 0.89 | PSMB5 (0.82) | PSMB5PSMB8PSMB9PSMB6PSMB10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1936 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| EP-4522764-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | Foundation Medicine, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| US-20250049800-A1 | VCP/p97 INHIBITOR FOR THE TREATMENT OF CANCER | CASI PHARMACEUTICALS INC (US) | 2025-02-13 | — | — | US | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | claimed |
| CN-118369102-A | VCP/p97 inhibitors for the treatment of cancer | 凯信远达医药公司 | 2024-07-19 | — | — | CN | claimed |
| EP-3664823-B1 | COMPOSITION FOR USE IN PREVENTING OR TREATING AN ENTEROCOCCAL BLOOD STREAM INFECTION | FINCH THERAPEUTICS HOLDINGS LLC (US) | 2024-06-05 | — | — | EP | claimed |
| US-20150361105-A1 | PROTEASOME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-17 | — | — | US | claimed |
| US-20150011506-A1 | Proteasome Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-08 | — | — | US | claimed |
| US-8871745-B2 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | claimed |
| US-20130331356-A1 | Proteasome Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-12-12 | — | — | US | claimed |
| US-20130096068-A1 | COMBINATION THERAPY WITH A PROTEASOME INHIBITOR AND A GALLIUM COMPLEX | NIIKI PHARMA INC. (US) | 2013-04-18 | — | — | US | claimed |
| EP-2527347-A1 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-11-28 | — | — | EP | claimed |
| EP-2178888-B1 | PROTEASOME INHIBITORS | MILLENNIUM PHARM INC (US) | 2012-07-04 | — | — | EP | claimed |
| EP-2178888-A1 | PROTEASOME INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2010-04-28 | — | — | EP | claimed |
| WO-2009020448-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | WO | claimed |
| US-7442830-B1 | Proteasome inhibitors | MILLENIUM PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331356-A1 | Proteasome Inhibitors | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20150011506-A1 | Proteasome Inhibitors | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20250049800-A1 | VCP/p97 INHIBITOR FOR THE TREATMENT OF CANCER | TP53, VCP, UBQLN2 | PSMB5 309/4885PSMB8 516/4885PSMB9 513/4885 |
| US-20130096068-A1 | COMBINATION THERAPY WITH A PROTEASOME INHIBITOR AND A GALLIUM COMPLEX | PSME1, PSMB5, PSMB1 | PSMB5 2/4885PSMB8 32/4885PSMB9 28/4885 |
| US-20150361105-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.